根据BioNTech管线图显示,下一代新冠疫苗在全球范围内与辉瑞合作,复星医药已丧失权益(BNT162b4 / BNT162b5)$复星医药(SH600196)$$BioNTech(BNTX)$
To expand T cell responses beyond the S protein, we developed BNT162b4, an mRNA vaccine component designed to boost cellular immunity against SARS-CoV-2. BNT162b4 encodes segments of the SARS-CoV-2 N, M, and ORF1ab proteins and is intended to be administered with S-protein-encoding vacci...